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ovel Risk
actors for Heart Failure
hen the Whole May Be
reater Than the Sum of Its Parts*
. Malcolm O. Arnold, MD, FACC,†
ichard E. Gilbert, MD, PHD‡
ondon and Toronto, Ontario, Canada
n a 19th century poem by John Godfrey Saxe (1), a group of
lind men touch an elephant to learn what it is like. Each one
ouches a different part, but only 1 part, obtaining varying
iews that depend on their perspectives, unable to conceive of
he entirety. Although knowing that we are in the midst of an
pidemic of glucose intolerance and diabetes that has devel-
ped as a consequence of excessive caloric intake and dimin-
shed activity, we remain unsure of its exact nature, defaulting
o the analysis of its parts from various perspectives. What is not
n dispute is its impact on ischemic heart disease and heart failure.
See pages 747 and 754
From one perspective, the epidemic is diabetes, where in the
.S. alone, more than 19 million people, or 9% of the
opulation, are affected (2), carrying with them an average
-fold independent increased risk of heart failure (3). Al-
hough, as physicians, we often prefer to examine risk factors as
ategorical phenomena, glycemia is a continuous variable like
lood pressure and low-density lipoprotein cholesterol. For
nstance, we have known for some time that among those with
iagnosed diabetes, long-term glycemic control correlates
losely with heart failure risk so that, after adjusting for
ssociated risk factors, a 1% increase in hemoglobin A1c is
ssociated with a 16% increase in heart failure risk over a
0-year period (4). More recently, we have also come to
ppreciate that just being nondiabetic does not mean normo-
lycemia. The intermediate category, variably called dysglyce-
ia or pre-diabetes, encompasses impaired fasting glucose and
mpaired glucose tolerance, and sometimes even includes those
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ntario, London, Ontario, Canada; and the ‡Keenan Research Centre in the Li Kar
hing Knowledge Institute and Division of Endocrinology, St. Michael’s Hospital
nd University of Toronto, Toronto, Ontario, Canada.atients with a high-normal fasting plasma glucose. Such
ysglycemic patients are at a higher risk of heart failure than
heir normoglycemic counterparts whose fasting plasma glu-
ose is 5.0 mmol/l (5).
Furthermore, those who view our burgeoning waistlines as
he primary problem will note that, among adult Americans,
6% are overweight or obese (32% obese) (6). Alterations in
ardiac structure and function are being increasingly recog-
ized, not only among the morbidly obese, but also in those
ith mild to moderate obesity, with clinical correlates that vary
rom asymptomatic left ventricular dysfunction to overt heart
ailure (7). Indeed, these findings have led to the proposal to
ecognize obesity cardiomyopathy as a diagnostic entity in
bese individuals with heart failure where other etiologies such as
oronary artery disease, diabetes, and hypertension are absent (7).
From another perspective, insulin resistance, manifested
linically as the variably defined metabolic syndrome, is the
rime mover. Like dysglycemia and obesity, metabolic syn-
rome is highly prevalent, affecting 27% of the U.S. population
8). Complicating the relationship between heart failure and
he metabolic syndrome is the finding that heart failure itself is
lso an insulin-resistant state (9). Two papers in this issue of the
ournal (10,11) explore these complex inter-relationships further.
To examine the prevalence of insulin resistance among heart
ailure patients, AlZadjali et al. (10) studied 129 patients who
ad been diagnosed with stable symptomatic systolic heart
ailure, after excluding those with a previous diagnosis of
iabetes or a fasting plasma glucose7.0 mmol/l (126 mg/dl),
he current threshold for the diagnosis of diabetes. Impaired
lucose tolerance was not assessed during screening. Of the
25 patients approached to participate in the study, 281 (54%)
ere excluded because of a current diagnosis of diabetes, a
revalence that is much higher than the more customary 25%
o 35% reported in most series (12). Among this study cohort
ecruited from inpatients, outpatient clinics, and community
eneral practice, 61% were found to be insulin resistant, and
his was associated with increased waist circumference and
erum leptin. Insulin resistance was also independently associ-
ted with worsening New York Heart Association functional
lass, a decrease in peak oxygen consumption, decrease in
xercise time, and endothelial dysfunction.
Adipose tissue, although initially regarded as a simple
epository of stored energy, has come to be recognized as a
omplex organ system, consisting of a range of cell types that
nclude not only adipocytes but also macrophages with which
hey share a common precursor. Although well known for its
bility to extrude various lipid moieties, adipose tissue is also
esponsible for the secretion of an array of polypeptides that
odulate inflammatory and metabolic pathways by both para-
rine and endocrine mechanisms. Included among them are 4
rincipal adipokines: leptin and adiponectin, which augment
nsulin sensitivity, along with resistin and retinol-binding
rotein 4, which diminish it (13). Resistin is a 12.5-kDa
ysteine-rich protein, named for its ability to induce insulin
esistance in rodents. However, more recent studies in humans
s
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Novel Risk Factors for HF March 3, 2009:763–4uggest that it may also have a prominent role in inflammation,
roviding a pathophysiological link between inflammation and
nsulin resistance (14). For instance, among its activities,
esistin induces p38 mitogen-activated protein kinase, a stress-
elated signaling cascade that has been implicated in the
evelopment of heart failure following myocardial infarction
15). Consistent with this, a cross-sectional 126-patient study
rom Japan found that serum resistin was elevated in heart
ailure patients when compared with 18 control subjects and
hat it increased in association with higher New York Heart
ssociation functional class (16).
The second paper reported in this issue by Frankel et al. (11)
xplores this new scientific front of the adipokines resistin and
diponectin, and the associated risk of developing heart failure.
he paper is particularly instructive, as it is a prospective study
rom the Framingham Offspring Study in which 2,739 subjects
ithout heart failure at baseline were followed for 6 years,
uring which time 58 participants (2%) developed new-onset
eart failure. Dividing circulating resistin concentrations into
ertiles and using a nested series of Cox proportional-hazards
egression models, the investigators found a hazard ratio for
eveloping heart failure of 2.89 for the middle tertile and 4.01
or the upper tertile relative to the lowest tertile. Moreover, this
elationship persisted after accounting for coronary artery
isease, body mass index, insulin resistance, C-reactive protein,
nd B-type natriuretic peptide.
Heart failure, like the elephant to a blind person, has many
ifferent ways in which it can be understood, depending on
here you stand. Numerous drug and nondrug strategies have
een developed over the last 20 years, based on the prevailing
echanistic understanding at the time. These advances have
uccessfully improved patient outcomes. Nonetheless, quality
nd quantity of life remain poor for many patients. At the
resent time, we still have much to learn about the complex
nter-relationships between dysglycemia, obesity, and insulin
esistance. However, their impact on heart failure and the
ardiovascular system is becoming clearer, with inflammation
merging as a possible unifying mechanism (13,17). Clinical
anagement of diabetes, obesity, and heart failure each re-
uires a multidisciplinary team approach. Ongoing interdisci-
linary research will hopefully provide us with a better under-
tanding of these emerging risk factors and potential
herapeutic targets that will allow us to see the full and correct
icture rather than just individual parts.
“And so these men of Indostan
Disputed loud and long,
Each in his own opinion
Exceeding stiff and strong,
Though each was partly in the right,
And all were in the wrong!”
—John Godfrey Saxe (1816–1887) (1)eprint requests and correspondence: Dr. J. Malcolm O.
rnold, University of Western Ontario, Victoria Campus 375
outh Street, London Health Sciences Center, Room S226A,
ondon, ON N6A 4G5, Canada. E-mail: malcolm.arnold@
hsc.on.ca.
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